UK cost group rejects drugs from AstraZeneca, Bristol and Roche



LONDON |
Thu Jan 31, 2013 7:32pm EST

LONDON (Reuters) – Britain’s medical cost watchdog NICE pronounced on Friday it was not means to suggest a new diabetes drug from Bristol-Myers Squibb and AstraZeneca, and has asked for some-more information from a companies.

The National Institute for Health and Clinical Excellence (NICE) has been deliberation Forxiga, or dapagliflozin, as an appendage therapy for use with other medicines, including insulin.

NICE, that decides if drugs should be paid for on a state health service, also pronounced it had released breeze superintendence not recommending Roche’s Avastin for ovarian cancer. The group has already deserted Avastin in other growth types.

(Reporting by Ben Hirschler; Editing by Elaine Hardcastle)

  • Twitter
  • Facebook
  • email
  • StumbleUpon
  • Delicious
  • Google Reader
  • LinkedIn
  • BlinkList
  • Digg
  • Google Bookmarks
  • HackerNews
  • Posterous
  • Reddit
  • Sphinn
  • Tumblr
  • Tumblr
  • Tumblr